Timetable: Post-authorisation measure (PAM) Paediatric art. 46 submission

Webinar on new approach methodologies (NAMs) in ecotoxicology: QSARs to predict aquatic toxicity, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 September 2026, 14:00 (CEST) to 17 September 2026, 15:30 (CEST)

Timetable: Post-authorisation measure (PAM) assessed by CAT

Timetable: Post-authorisation measure (PAM) assessed by CHMP

Timetable: Post-authorisation measure (PAM) Paediatric art. 46 submission - ATMP

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 53, Status: Authorised

Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Date of authorisation: 03/12/2010, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Tuznue, trastuzumab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 16, Status: Authorised

PSUSA/00000548/202510